Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor recently approved by the FDA as an extended adjuvant treatment for patients with HER2+ early-stage breast cancer that does not cause severe adverse effects, except diarrhea26. The gene discussed is ERBB2; the disease is breast carcinoma.